Bin Zhang - Bioatla Senior Development
| BCAB Stock | USD 1.68 0.04 2.44% |
Executive
Bin Zhang is Senior Development of Bioatla
| Address | 11085 Torreyana Road, San Diego, CA, United States, 92121 |
| Phone | 858 558 0708 |
| Web | https://www.bioatla.com |
Bioatla Management Efficiency
The company has return on total asset (ROA) of (0.5047) % which means that it has lost $0.5047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3906) %, meaning that it created substantial loss on money invested by shareholders. Bioatla's management efficiency ratios could be used to measure how well Bioatla manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -1.08. The current year's Return On Capital Employed is expected to grow to -1.35. At present, Bioatla's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 217.8 M, whereas Non Currrent Assets Other are forecasted to decline to about 158.9 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Leonard MD | C4 Therapeutics | 62 | |
| Jeremy Chadwick | Kymera Therapeutics | 61 | |
| JD Esq | Passage Bio | 60 | |
| Eric JD | Nurix Therapeutics | 57 | |
| Daron Evans | Rezolute | 50 | |
| Robert JD | Pmv Pharmaceuticals | 62 | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Nick MD | Century Therapeutics | N/A | |
| Subra Sankar | Nautilus Biotechnology | 65 | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Stephen JD | Shattuck Labs | 49 | |
| Erin OBoyle | Rezolute | N/A | |
| MS MBA | Rezolute | 50 | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| Courtney OKonek | Olema Pharmaceuticals | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.5 |
Bioatla Leadership Team
Elected by the shareholders, the Bioatla's board of directors comprises two types of representatives: Bioatla inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bioatla. The board's role is to monitor Bioatla's management team and ensure that shareholders' interests are well served. Bioatla's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bioatla's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gerhard Frey, Senior Development | ||
| Cathy Chang, Senior Development | ||
| Christian CPA, Controller Officer | ||
| Sheri Lydick, Chief Officer | ||
| Philippe Martin, Chief Operations | ||
| Monica Sullivan, Senior Contracts | ||
| Christian Vasquez, Controller Officer | ||
| Lisa Pelton, Accounting Manager | ||
| Scott Smith, Pres Director | ||
| Susie Melody, Senior Resources | ||
| Jay Short, CEO CoFounder | ||
| Eric MD, Chief Officer | ||
| Richard Waldron, Chief Officer | ||
| Bin Zhang, Senior Development | ||
| MSc MD, Senior Development |
Bioatla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bioatla a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 24.7 M | ||||
| Shares Outstanding | 48.35 M | ||||
| Shares Owned By Insiders | 10.75 % | ||||
| Shares Owned By Institutions | 42.85 % | ||||
| Number Of Shares Shorted | 4.14 M | ||||
| Price To Book | 3.54 X | ||||
| Price To Sales | 7.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bioatla offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bioatla's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioatla Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioatla Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share 0.228 | Quarterly Revenue Growth 0.316 | Return On Assets (0.50) | Return On Equity (1.39) |
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioatla is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.